✨ Today’s Pharma Daily Digest delivers critical insights that are reshaping the future of hashtag #metabolics and hashtag #cardiovascular treatments. Here’s a glance at the biggest developments that you need to know. 🔺BridgeBio's BEYONTTRA for ATTR-CM Wins EU Approval, Triggering $75 Million Milestone Payment. 🔺Novo Nordisk launches "Check Before You Inject" campaign to verify semaglutide authenticity, following Hims & Hers' Super Bowl ad on GLP-1 drug risks. 🔺Novartis to Acquire Anthos Therapeutics for Up to $3.1 Billion, Focusing on Abelacimab for Stroke Prevention. 🔺Eli Lilly and Company Signs $630M Deal with OliX for OLX75016, Boosting OliX’s Stock by 30%. Deal Grants Lilly Priority Rights for Metabolic Disorder Therapies. 🔺The PRESTIGE-AF phase 3b trial, coordinated by Imperial College London, shows DOACs reduce stroke risk in ICH and AF patients. It was funded by the EU's Horizon 2020 program. 🔺Alexion Pharmaceuticals, Inc., in partnership with Kidney Care UK, developed the interactive storybook "Revealing the Secrets of aHUS" to educate children about aHUS in an engaging and supportive way. 🔻LANCET Pharmaceuticals's New Obesity Definition Faces Criticism; Rubino Clarifies Treatment Focus on Risk, Not Classification. ----- 💡 Sign up for our Daily Digest to stay updated on the pharma and biotech advancements shaping tomorrow’s healthcare breakthroughs. Don’t miss the insights that could impact your next strategic move! #PharmaDailyDigest #Pharmaceuticals #Biotech #CompetitiveIntelligence #AtacanaGroup #Lancet #NovoNordisk #Alexion #Elililly #Novartis
